Waters (WAT) Stock Forecast & Price Target

Waters is supported by a rare combination of durable end-market demand, with roughly 60% of sales tied to pharma and about 15% of sales exposed to drug manufacturing, where spending is driven by regulated QA/QC and manufacturing activity rather than volatile research budgets. Its core analytical-instrument franchise is accelerating, as legacy Waters delivered 10% instrument growth and 12% chemistry growth, while Q3 organic revenue rose 10% and management lifted full-year constant-currency growth guidance to 9.1%–9.7%. The early 2026 Becton Dickinson merger adds a turnaround and consolidation lever, with improving pricing, China localization, and expected synergy and margin benefits, while the new diagnostics and proteomics exposure broadens the growth runway.

Waters is facing a negative setup because the BD acquisition brought in businesses with weakening trends, increasing operational complexity and the risk that integration issues and underperformance permanently dilute organic sales growth. The deal also adds about $4B of assumed debt on top of existing debt, constraining capital allocation flexibility and leaving the balance sheet less able to support additional strategic or tactical actions near term. Even though its core analytical instruments business had been growing well, post-COVID demand benefits and easier 2019 comps make that momentum harder to sustain, and multiple compression could follow if core growth decelerates while the acquired BD assets disappoint.